CureVac is a leading clinical-stage biopharmaceutical company in Germany, based in Tübingen. It is very successful in developing special m-RNA based vaccine technologies, an approach which has been awarded by the EU vaccine prize recently. Its outstanding expertise now encourages the Bill & Melinda Gates Foundation to invest €46M in the company and to support several projects separately. Additionally Dietmar Hopp, representative of CureVac’s longlasting German investor dievini Hopp BioTech, announced further investment of €21M.
CureVac’s technology uses mRNA molecules that stimulate the immune system and let the body produce its own medicine. Its platform allows the production of thermostable vaccines in very short times and the secure delivery of these to the most remote areas of the world. As the company explains by press release, the Gates’ investmentwill support continued development of the platform technology and the construction of an industrial scale production facility. Both partners will collaborate on the development and production of numerous vaccines against infectious diseases that disproportionately affect people in the world’s poorest countries. The separate funding concerns projects developing vaccines for viral, bacterial and parasitic infectious diseases, starting with the development of vaccines against rotavirus and HIV.
“With the Bill & Melinda Gates Foundation we have found another strong and highly committed investor to support us in expanding our mRNA platform at an accelerated pace”, said Ingmar Hoerr, co-founder and CEO of CureVac.
The company, founded without any investor in 2000, is an impressive example of biopharmaceutical entrepreneurship in Southwestern Germany. Besides prophylactic vaccines it has been developing novel mRNA-based cancer immunotherapies, especially for the treatment of lung cancer and prostate cancer, which are currently tested by clinical studies.
Further Information: www.curevac.com
Let's Continue The Conversation
Feel free to send us comments about this article to email@example.com and/or comment on that article on social media.